Supersized bought deal Field Trip (FTRP.CN) announced on Friday that it raised a whopping $95.3M CAD through a bought deal. The deal was originally for
For a year, naysayers have dismissed the early stage shroom boom as being a pumpy bunch of pubco RTOs that won’t be able to do
Mydecine Innovations Group (MYCO.C) expanded their relationship with Applied Pharmaceutical Innovation (API) to include the University of Alberta in support of multiple drug development and
Cut the kumbaya shit Throwing the words profit and psychedelic drugs into a sentence would have lead to awkward and confused looks 5 years ago.
I’ve made no secret of the fact that the Canadian cannabis market frequently annoys the hell out of me. What I want is for it
Regular readers with an interest in psychedelics will know we recently started talking to a company called Delic Holdings (DELC.C), and that it was a
Xphyto describes itself as “a bioscience accelerator” “targeting growth through commercialization of its product pipeline”.
Core One Labs (COOL.C) subsidiary Vocan Biotechnologies finished putting together the required equipment to start artificially producing psilocybin today, according to a press release. Acquired
Revive Therapeutics (RVV.C) and 17 other companies in the United States and Canada joined the first psychedelic exchange-traded fund, managed by Horizons ETF management today,
If we’re honest about it – if we’re REALLY honest about it – Canada has fumbled its advantage in the cannabis sector. First to market,
In lieu of the American markets not opening today courtesy of the civic holiday, Xphyto Therapeutics (XPHY.C) has elected to provide a glimpse into their
Revive Therapeutics (RVV.C) entered into a sponsored research agreement and license agreement with North Carolina State University (NC State), developing a biosynthetic version of psilocybin
Core One’s objective in developing the psilocybin thinstrips is to assist with the delivery of revolutionary psychedelic treatment methods to address mental health conditions such as depression, anxiety and addictions.
The company’s platform includes “The Delic”, an e-commerce lifestyle brand, “Reality Sandwich”, a free public education platform and “Meet Delic” – a psychedelic wellness summit with its first planned event on May 1, 2021 in Los Angeles.
“This transaction will significantly enhance Core One Labs’ ability to innovate our psychedelic drug development program,” stated Joel Shacker, CEO of Core Labs.
The notion of magic mushroom market offering after the legalization of cannabis has been floated time and again since long before cannabis legalization was even
Pure Extracts is targeting the commercial cannabis and psychedelics sector, backed by deep extraction and production expertise.
Investor focus is currently bifurcated between a potential FDA bucillamine approval, and RVV’s ambitions and partnerships in the shroom space.
Red Light Holland (TRIP.C) is up 17.1% on the day, culminating in a blast-off trend that’s seen them rise from last month’s high of $.07
Halted since July of this year, right in the midst of a six week rise, the pubco formerly known as Lifestyle Delivery Systems, now Core
If this was a 1990’s news website we’d be putting all sorts of animated siren gifs all over the top of this piece because, I
Barely a few weeks after telling the Equity.Guru audience that the timeline on mushrooms would see Pure Extracts (PULL.C) focusing on its core cannabis market,
Smallcap investors largely see the psychedelics space in one of two ways; you’re either in the ‘this may be big one day but there’s not
Yeah, I know, I know. Canadian cannabis companies are ass right now, and have been for a few years. Trust me, I’m about as out
Let’s talk for a moment about Measure 109. The measure was a vote on whether or not to allow licensed service providers the ability to
Earlier this year, when Revive Therapeutics (RVV.C) announced they had some pharma IP that may be relevant to the treatment of COVID-19, plenty of folks
Pharmadrug’s (BUZZ.C) subsidiary Interrobang, itself doing business as Super Smart, closed the transaction to acquire a brick and mortar store specializing in selling psychedelic products
Revive has a partnership agreement with the Reed Research Group out of the University of Wisconsin-Madison to evaluate novel formulations of psilocybin.
Mydecine Innovations Group’s (MYCO.C) subsidiary Mindleap Health expanded its digital therapeutic services, dealing specifically with addiction, by adding three new programs to its platform. This
Formerly dismissed-by-many pharmaceutical company Revive Therapeutics (RVV.C) jumped a whopping 68% Friday upon revealing it has been granted approval to move forward with phase 3
War is a part of human nature. It’s the greatest driver of human innovation, and if we’re inclined to be cynical we could state that
Numinus Wellness (NUMI.V) is the first company to receive the Health Canada nod to standardize the extraction of psilocybin from mushrooms. The Health Canada nod
A randomized, double-blind trial from Johns Hopkins in 2016 found that a single dose of psilocybin substantially improved quality of life and decreased depression and
When the history books are written on this passage of our lives, under pandemic lockdown and with once-in-three-generations levels of unemployment, they’ll note that in
Revive Therapeutics is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases including influenza and the coronavirus disease (Covid-19)
A cannabis company producing another build-out, another dispensary or pushing forward incrementally isn’t what necessarily passes newsworthy muster. This isn’t 2017 anymore, and it’s generally
Mind Medicine (MMED.E) has worked together with University Hospital Basel’s Liechti Laboratory to discover and file and patent application in the United States for a
The long and short of it is that psychedelics aren’t here yet. There are plenty of companies in various stages of development, doing what they
Oddball pharmaceutical player Revive Therapeutics (RVV.C) found itself on the back end of a warning by the BCSC this week, that certain German players in the smallcap promotion space had over-hyped the mushroom/cannabis/biotech deal and promised big wins inappropriately for anyone who invested. As a marketing partner of Revive, I got a few panicky texts from certain folks wondering if that meant trouble for us – or them. It’s not a problem for us; our coverage has been appropriately even-handed.
When new sectors emerge, as cannabis did in 2013 and psychedelics are doing right now, microcap companies that have struggled in other sectors will often pivot into new business. Miners become weed companies, then biotech companies, then shroom companies, as boards and management pursue new opportunities that might one day prove better than the last.
Today was a day that daytraders have been looking forward to for some time; the day that shroom stocks finally gripped the road and took off. Mind Medicine (MMED.E) ripped 90% to $0.77 on the back of 15m shares traded, reminding anyone who’d listen that ex-Canopy CEO Bruce Linton and pretend billionaire Kevin O’Leary were on board. Champignon Brands (SHRM.C) zoomed 40% to $0.33 on a lot smaller market awareness spend byt a handy ticker, Roadman Investments (LITT.V) was up 30% to $0.065 being sucked along in the other two companies’ wake, and Revive Therapeutics (RVV.C) was up 81% to $0.10 on ripples caused by the rest.
